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 The mainstay protocol exercised by global 
health leaders to control the spread of severe acute 
respiratory syndrome corona virus (SARS-CoV-2) 
has been screening, the identification of cases, 
isolation thereof, contact tracing and nation-wide 
lockdowns. The development of vaccinations against 
the SARS-CoV-2 virus has marked a new dawn for 
the war against corona virus disease (COVID-19).
[1,2]
First generation immunization against 
COVID-19:
 The first set of vaccinations to be produced 
were Janssen and Novavax, Johnson and Johnson, 
Oxford AstraZeneca, Pfizer-BioNTech, Moderna, 
and Covaxin. All of these produce various side ef-
fects with some to the severity that multiple deaths 
have been recorded. This first generation of vaccines 
developed against COVID-19 are all administered 
via the conventional intramuscular route. A more 
alarming fact is that this first generation of vaccines 
have a dwindling efficacy and confer little immunity 
against the new variants of the SARS-CoV-2 virus.
[3]
Second generation immunization against 
COVID-19:
 With the innate drawbacks and side effects of 
the traditional vaccines, coupled with the discovery 
of the new variants of the SARS-CoV-2 virus; a 
newer second generation of immunization against 
the virus is under development. The two new novel 
methods of immunization are the intranasal vaccine 
by Oxford Astra Zeneca taking place at Oxford 
University’s Jenner Institute and the oral vaccine 
which is being developed by Oravax Medical, a 
joint venture between an Israeli-American company 
known as Oramed and the Indian company Premas 
Biotech.[4,5,6]
COVID-19 intranasal vaccine:
 The intranasal route of drug administration 
has been a popular route of delivery for drugs such 
as antihistamines. It is a rapid, easy, cost effective 
and high yield route for drug administration. The 
intranasal vaccine has been developed and is based 
on a poultry virus which has been designed to 
produce the spike proteins of SARS-CoV-2. It has 
shown promising results in animal studies, with a 
marked decrease and stoppage of viral shedding. 
This vaccine has now entered phase 1 clinical trials. 
[4,5,6,7]
Advantages of the intranasal vaccine:
 The cost effectiveness will allow for a 
greater international production capacity. The 
ease of administration nullifies the need for highly 
trained medical and paramedical staff. This innate 
advantage makes this vaccine a better hope for the 
planet to maintain herd immunity at a more rapid 
and safe rate due to its scalability. It is indicated 
that COVID vaccines will have to be developed 
alongside the discovery of new variants, thus making 
the vaccine an annual or even biannual necessity. 
Mass immunization is a monumental and logistical 
nightmare and thus a vaccine administered via the 
intranasal will make such vaccination campaigns 
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 The oral vaccine is based off of the protein 
oral delivery (POD) system developed by Oramed.
[6] It is developed using a virus like particle (VLP), 
it will be a triple antigen vaccine with the intent to 
hone in on three important viral structural proteins. 
The premise of the vaccine will be to evoke both 
a systemic and local immune response via IgA 
and IgG. Current animal pilot studies have shown 
promising results with antibody production after a 
single capsule dose.[10,11]
Advantages of the oral vaccine:
 The oral vaccine will be both a more cost 
effective and widely greater accepted method of 
receiving the immunization. The production output 
of the oral vaccine coupled with its hardy nature and 
no need for a sophisticated cold chain will ensure 
people in the most remote and rural settings will 
have access to the vaccine. Nepal is an example 
where the distribution of drugs on a wide basis is 
challenging due to economical, topographical and 
transportation obstacles; the oral route will thus make 
the attainment of herd immunity in such a nation a 
feasible possibility. The oral vaccine will confer a 
double layer of both systemic and local immunity, 
via IgA and IgG secretion thus decreasing shedding.
[6]
Patient compliance:
 The intranasal route is a painless route 
of administration. It is less invasive and is needle 
free thus ensuring that patients suffering from 
trypanophobia will not be averse to being immunized. 
The ability of a patient to self-administer the vaccine 
will aid and increase patient compliance, thus aiding 
and boosting immunization rates.[9]
 The familiarity of oral administration and 
ease of use of this vaccine will increase patient 
compliance as the process of taking the vaccine will 
not be an entirely foreign concept.[10]
Storage:
 An innate challenge with the conventional 
first generation of vaccinations was the sanctity of 
the cold chain. The intranasal vaccine will eliminate 
these complications as storage would be simpler 
and more cost effective and thus make the logistical 
supply chain more feasible.[11]
Shelf life:
 The first-generation vaccinations have 
a short shelf-life which has led to the expiry of 
thousands of doses. Both the oral and intranasal 
vaccines will have a longer shelf-life and will thus 
reduce wastage whilst simultaneously allowing for 
the better management of the international vaccine 
supply, thereby optimizing the vaccination rollout.
[12]
Conclusion:
 The only long-term solution to this deadly 
pandemic will be the establishment of herd immunity 
across the entire globe. The current vaccinations 
available on the market are proving near impossible 
to achieve herd immunity with, due to a plethora of 
drawbacks. The new variants of COVID-19 are of 
a great concern and thus, it is believed that a yearly 
“flu-like” immunization against COVID-19 will 
be a necessity in future. The current vaccinations 
available on the market will not suffice and thus it 
is evident that the second generation via their novel 
routes of administration have both the cost and 
scalability potential to ensure a global vaccination 
roll out which is logistically sound and plausible.
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